| Code | CSB-RA006163MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LM-168, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. This interaction delivers inhibitory signals that dampen immune responses and maintain peripheral tolerance. Dysregulation of CTLA4 signaling is implicated in various autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease, while its expression on regulatory T cells contributes to tumor immune evasion in multiple cancers.
LM-168 serves as a reference antibody for investigating CTLA4-mediated immune regulation and checkpoint blockade mechanisms. This biosimilar provides researchers with a reliable tool for studying T-cell activation dynamics, immune tolerance pathways, and therapeutic strategies targeting immune checkpoints. It supports investigations in immunology, oncology, and autoimmune disease research, facilitating the development of novel immunotherapeutic approaches.
There are currently no reviews for this product.